{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:54:57Z","timestamp":1781499297564,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic lymphoma kinase (ALK)\u2013rearranged renal cell carcinoma (ALK-RCC) is a rare provisional entity characterized by fusion of the ALK gene with various fusion partner genes, resulting in oncogenic activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a 39-year-old Chinese man with ALK-RCC who underwent partial nephrectomy for a left renal tumor measuring 2.8 \u00d7 2.7\u00d7 2.6\u00a0cm. Histopathological examination revealed a renal epithelial tumor with atypical morphology. Immunohistochemistry demonstrated the occurrence of renal epithelial differentiation and excluded other entities. Next-generation sequencing confirmed a KIF5B-ALK gene fusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case presents the clinical data, morphology, immunohistochemistry, and molecular characteristics of a rare subtype of ALK\u2013rearranged renal cell carcinoma with KIF5B-ALK fusion. The findings may enhance the clinical and pathological understanding of ALK-RCC among clinicians and pathologists. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene may have a role in patients with ALK-RCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1825447","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:26:58Z","timestamp":1781497618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: KIF5B-ALK\u2013rearranged renal cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaxi","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Urology, Zhangye People\u2019s Hospital Affiliated to Hexi University","place":["Zhangye, China"]},{"name":"Institute of Urology, Hexi University","place":["Zhangye, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, Wuqing District Second People\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, Chengwu County People\u2019s Hospital","place":["Heze, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology, Wuqing District Second People\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2174\/0113892037291318240130103348","article-title":"A review on anaplastic lymphoma kinase (ALK) rearrangements and mutations: implications for gastric carcinogenesis and target therapy","volume":"25","author":"Mesquita","year":"2024","journal-title":"Curr Protein Pept Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.25","article-title":"ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies","volume":"7","author":"Poei","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2021-0330-oa","article-title":"ALK translocation in ALK-positive mesenchymal tumors: diagnostic and therapeutic insights","volume":"146","author":"Jung","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113927","article-title":"ALK upregulates POSTN and WNT signaling to drive neuroblastoma","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.05.014","article-title":"ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases","volume":"56","author":"Wang","year":"2024","journal-title":"Pathology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213624","article-title":"Overexpression of fibroblast growth factor 8 is a predictor of impaired survival in esophageal squamous cell carcinoma and correlates with ALK\/EML4 alteration","volume":"16","author":"Jomrich","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.213","article-title":"Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum","volume":"24","author":"Debelenko","year":"2011","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5114\/pjp.2018.76693","article-title":"A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects","volume":"69","author":"Kuroda","year":"2018","journal-title":"Pol J Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-015-0660-1","article-title":"Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning","volume":"38","author":"Song","year":"2015","journal-title":"Arch Pharm Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5146\/tjpath.2020.01507","article-title":"ALK-positive histiocytosis: a case report and literature review","volume":"37","author":"Jaber","year":"2021","journal-title":"Turk Patoloji Derg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.107","article-title":"ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients","volume":"25","author":"Sukov","year":"2012","journal-title":"Mod Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27391","article-title":"Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method","volume":"118","author":"Sugawara","year":"2012","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"154951","DOI":"10.1016\/j.prp.2023.154951","article-title":"ALK-rearranged renal cell carcinoma (ALK-RCC): evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey","volume":"253","author":"Dogan","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4132\/koreanjpathol.2013.47.5.452","article-title":"ALK-positive renal cell carcinoma in a large series of consecutively resected Korean renal cell carcinoma patients","volume":"47","author":"Lee","year":"2013","journal-title":"Korean J Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-540-85516-3_1243","article-title":"Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review","volume":"71","author":"Yu","year":"2017","journal-title":"Histopathology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152669","article-title":"ALK-rearranged renal cell carcinomas in Polish population","volume":"215","author":"Gorczynski","year":"2019","journal-title":"Pathol Res Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04292-2","article-title":"ALK-rearranged renal neoplasms: update on an institutional cohort","volume":"487","author":"Arizpe","year":"2025","journal-title":"Virchows Arch"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.155814","article-title":"Renal cell carcinoma with ALK-TPM3 gene fusion and ALK amplification: a case report and literature review","volume":"266","author":"Tu","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd013453","article-title":"Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"1","author":"Cameron","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050384","article-title":"Sustained improvement in the management of patients with non-small-cell lung cancer (NSCLC) harboring ALK translocation: where are we running","volume":"30","author":"Spitaleri","year":"2023","journal-title":"Curr Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.032","article-title":"Responses to alectinib in ALK-rearranged papillary renal cell carcinoma","volume":"74","author":"Pal","year":"2018","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1343","article-title":"Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review","volume":"9","author":"Zhou","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1701\/3525.35133","article-title":"Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report","volume":"112","author":"Varchetta","year":"2021","journal-title":"Recenti Prog Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2016.07.004","article-title":"TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: report of a case with a TPM3-ALK translocation","volume":"212","author":"Thorner","year":"2016","journal-title":"Pathol Res Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102266","article-title":"ALK-rearranged renal cell carcinoma: a study of three cases with clinicopathologic features and effect of postoperative adjuvant immunotherapy","volume":"23","author":"Zhang","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.32948\/auo.2024.08.22","article-title":"Renal cell carcinoma with sarcomatoid and rhabdoid dedifferentiation: clinico pathological significance- review","volume":"7","author":"Jagtap","year":"2024","journal-title":"Ann Urol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0578-0","article-title":"ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217","volume":"33","author":"Kuroda","year":"2020","journal-title":"Mod Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825447\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:27:20Z","timestamp":1781497640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1825447\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1825447"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1825447","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1825447"}}